16051-48-2

Basic information

• Product Name: 2-hydroxyethyl nitrate
• Synonyms: 2-hydroxyethyl nitrate;1,2-Ethanediol 1-nitrate;Ethylene glycol mononitrate;1,2-Ethanediol, mononitrate;Einecs 240-196-7
• CAS NO: 16051-48-2
• Molecular Formula: C₂H₅NO₄
• Molecular Weight: 107.0654
• EINECS: 240-196-7
• Mol File: 16051-48-2.mol
• Article Data: 18

Chemical Properties

• Boiling Point: 96.5°Cat760mmHg
• Flash Point: 12.2°C
• Appearance: /
• Density: 1.369g/cm³
• Vapor Pressure: 25.3mmHg at 25°C
• Refractive Index: 1.44
• PKA: 13.82±0.10(Predicted)
• CAS DataBase Reference: 2-hydroxyethyl nitrate(CAS DataBase Reference)
• NIST Chemistry Reference: 2-hydroxyethyl nitrate(16051-48-2)
• EPA Substance Registry System: 2-hydroxyethyl nitrate(16051-48-2)

Safety Data

• Hazardous Substances Data: 16051-48-2(Hazardous Substances Data)

Usage

General Description

2-Hydroxyethyl nitrate is a nitrate ester that is produced by the nitration of ethylene glycol. It is commonly used as a fuel additive in diesel engines to improve combustion efficiency and reduce emissions. 2-Hydroxyethyl nitrate functions as a cetane number improver, which enhances ignition quality and leads to smoother and more efficient engine operation. It also serves as a potential alternative to traditional diesel fuel additives and has shown promise in improving fuel economy and reducing particulate matter and nitrogen oxide emissions. However, it is important to handle 2-hydroxyethyl nitrate with caution as it is flammable and can cause irritation to the skin and eyes upon contact.

InChI:InChI=1/C2H5NO4/c4-1-2-7-3(5)6/h4H,1-2H2

Upstream product

• 75-21-8 oxirane 
• 67-56-1 methanol 
• 66329-10-0 1-nitritoethan-2-ol nitrate 
• 540-51-2 2-bromoethanol 
• 107-21-1 ethylene glycol 
• 107-07-3 2-chloro-ethanol 

Downstream Products

• 80444-43-5 2-Methoxy-aethylnitrat 
• 128759-76-2 VA-045 
• 1346223-09-3 2-(nitrooxy)ethyl-2-[1-phenyl-2-methyl-5-(4-methylsulphonylphenyl)-1H-pyrrol-3-yl]acetate 
• 1346223-11-7 2-(nitrooxy)ethyl-2-[(1-(3-fluorophenyl)-2-methyl-5-(4-methylsulphonylphenyl)-1H-pyrrol-3-yl)]acetate 
• 1346223-17-3 2-(nitrooxy)ethyl-2-[1-(4-methoxyphenyl)-2-methyl-5-(4-methylsulphonylphenyl)-1H-pyrrol-3-yl]-acetate 
• 1346223-13-9 2-(nitrooxy)ethyl-2-[(1-(4-fluorophenyl)-2-methyl-5-(4-(methylsulphonyl)phenyl)-1H-pyrrol-3-yl)]acetate 
• 1346223-15-1 2-nitroxyethyl 2-[1-[(4-methylthio)phenyl]-2-methyl-5-[4-(methylsulfonyl)phenyl]-1H-pyrrol-3-yl]acetate 
• 1538580-25-4 (Z)-4-(nitrooxy)butyl 2-(5-fluoro-2-methyl-1-(4-(methylsulfinyl)benzylidene)-1H-inden-3-yl)acetate 
• 1538580-30-1 (Z)-2-(nitrooxy)ethyl 2-(5-fluoro-2-methyl-1-(4-(methylthio)benzylidene)-1H-inden-3-yl)acetate 
• 1538580-35-6 (Z)-2-(nitrooxy)ethyl 2-(5-fluoro-2-methyl-1-(4-(methylsulfonyl)benzylidene)-1H-inden-3-yl)acetate 
• 1068441-02-0 (±)-2-(nitrooxy)ethyl 2-(3-benzoylphenyl)propanoate 

Relevant articles and documents

-

-

-

-

Design, synthesis and study of nitrogen monoxide donors as potent hypolipidaemic and anti-inflammatory agents

Inflammation and oxidative stress are involved in cardiovascular diseases. Nitrogen monoxide participates in the regulation of endothelial processes. Thus, derivatives of classic nonsteroidal anti-inflammatory drugs (NSAIDs), trolox or cinnamic acids esterified with 2-(nitrooxy)ethanol were designed and studied. It was found that the nitrogen monoxide (NO) releasing activity was comparable to that of S-nitroso-N-acetylpenicillamine. The nitrooxy derivatives decreased potently lipid indices in the plasma of hyperlipidaemic rats (30-85%). All compounds presented increased anti-inflammatory activity in vivo, inhibiting carrageenan-induced rat paw oedema as high as 76%, up to six times higher than that of the parent acids. Lipoxygenase inhibitory activity was significant for most of them, although the parent molecules exerted a minor effect (IC50 > 0.2 mM). Those compounds incorporating an antioxidant structure inhibited rat microsomal membrane lipid peroxidation strongly and possessed radical scavenging activity. These results indicated that the described compounds could act at different targets in multifactorial diseases, further limiting the possible adverse effects of drug combinations.

Nitrate NO donor type evodiamine derivatives with anti-tumor activity

The invention relates to the field of natural medicines and medicinal chemistry and particularly relates to derivatives with modified 13-N of evodiamine. The invention discloses a preparation method of the 13-N nitrate NO donor substituted evodiamine derivatives and evaluation of the anti-tumor activity. The structure of the derivatives is shown in the specification, wherein R is (CH2)n, and n is an integer between 1 and 8.